Drugs / nL-TARDB-002
re-read 3 minutes ago

nL-TARDB-002

Developed for
amyotrophic lateral sclerosis
Investigated by
Thomas Jefferson University · n-Lorem Foundation

Trials 1

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07703462 Dec 2026 → Dec 2028 expected amyotrophic lateral sclerosis n-Lorem Foundation Enrolling by invitation No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as nL-TARDB-002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07703462 ↗